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ABSTRACT
Background: The management of human epidermal
growth factor receptor 2 (HER2)-positive breast cancer
(BC) has changed dramatically with the introduction
and widespread use of HER2-targeted therapies.
However, there is relatively limited real-world
information on patterns of use, effectiveness and safety
in whole of population cohorts. The research
programme detailed in this protocol will generate
evidence on the prescribing patterns, safety monitoring
and outcomes of patients with BC treated with HER2-
targeted therapies in Australia.
Methods/design: Our ongoing research programme
will involve a series of retrospective cohort studies that
include every patient accessing Commonwealth-funded
HER2-targeted therapies for the treatment of early BC
and advanced BC in Australia. At the time of writing,
our cohorts consist of 11 406 patients with early BC
and 5631 with advanced BC who accessed
trastuzumab and lapatinib between 2001 and 2014.
Pertuzumab and trastuzumab emtansine were publicly
funded for metastatic BC in 2015, and future data
updates will include patients accessing these
medicines. We will use dispensing claims for cancer
and other medicines, medical service claims and
demographics data for each patient accessing HER2-
targeted therapies to undertake this research.
Ethics and dissemination: Ethics approval has been
granted by the Population Health Service Research
Ethics Committee and data access approval has been
granted by the Australian Department of Human
Services (DHS) External Review Evaluation Committee.
Our findings will be reported in peer-reviewed
publications, conference presentations and policy
forums. By providing detailed information on the use
and outcomes associated with HER2-targeted therapies
in a national cohort treated in routine clinical care, our
research programme will better inform clinicians and
patients about the real-world use of these treatments
and will assist third-party payers to better understand
the use and economic costs of these treatments.
INTRODUCTION
Ampliﬁcation of the human epidermal
growth factor receptor 2 (HER2) oncogene
is present in ∼20–30% of breast cancers
(BCs).1 The discovery of new and effective
HER2-targeted therapies over the past
20 years has signiﬁcantly improved the out-
comes of patients with this aggressive BC
subtype. Compared to cytotoxic chemother-
apy alone, the addition of HER2-targeted
therapies signiﬁcantly improves response
rates, disease-free survival (DFS)/
progression-free survival (PFS) and overall
survival (OS) in patients with HER2-positive
BC treated in the neoadjuvant, adjuvant or
metastatic settings.2–12
While randomised clinical trials remain
the gold standard for demonstrating treat-
ment efﬁcacy, they have some limitations as
an evidence-base. The selected population
enrolled in a clinical trial is not always repre-
sentative of the population of ‘all comers’ in
routine practice where patients are often
older, have more extensive disease, poorer
clinical status and more comorbidities. The
Strengths and limitations of this study
▪ One of the largest and only whole-of-country
HER2-positive cohorts, internationally.
▪ Currently up to 13 years of data observation, to
be extended with future data updates.
▪ Linked medical services and medicines dispens-
ing data for some patients.
▪ Lack of clinical measures such as Eastern
Cooperative Oncology Group status and Tumour/
Nodes/Metastasis staging.
▪ Lack of clinical diagnoses of comorbidities,
adverse events and cancer progression events.
Daniels B, et al. BMJ Open 2017;7:e014439. doi:10.1136/bmjopen-2016-014439 1
Open Access Protocol
sample size and duration of follow-up in clinical trials
are often insufﬁcient to detect infrequent events and to
determine long-term outcomes.13–15 As a consequence,
medicines can be released to market before their risk
beneﬁt proﬁle is fully evaluated, especially when there is
increasing demand for early access to potentially life-
saving medicines. Observational studies of unselected
cohorts of patients are a valuable means of assessing the
long-term impact of medicines and their patterns of use
in routine practice.16 17
In the past decade, a number of observational studies
have examined outcomes associated with HER2-targeted
therapies in routine clinical practice, using data from
prospective registries, hospital records and routinely col-
lected, population-based administrative data. The hetero-
geneity in the available data used by these studies has
driven their focus. Registry-based and hospital-based
data typically include records for relatively smaller
numbers of patients observed for short periods of time,
but contain detailed clinico-pathological measures allow-
ing for studies of the associations between these clinical
factors and outcomes such as patterns of care following
relapse, adverse events, OS and DFS/PFS.18–34
Population-based data are often maintained for pur-
poses of reimbursement/payment and tend to have
fewer clinical details, but offer much larger sample sizes
across healthcare settings providing evidence more rep-
resentative of general populations and allowing for
better detection of rare events. To date, studies using
population-based administrative data to examine the use
of HER2-targeted agents in routine care have focused
primarily on trastuzumab, and, to a lesser extent lapati-
nib, examining safety and long-term outcomes (table 1,
columns 1 and 2). Most of these studies have been
conducted in North America, over a period of 5–10
observation years, in populations of up to 4000
patients. The majority of studies have focused on cardio-
toxicity39 40 43–49 and reported an increased risk of cardi-
otoxicity associated with trastuzumab treatment. A
limited number of studies examined cardiac monitoring
before and during trastuzumab therapy for metastatic
BC (MBC), each reporting less than half of patients
underwent an assessment of cardiac function prior to
initiation of therapy (range 11–38%).35–37
Population-based study estimates of survival outcomes
for women receiving HER2-targeted therapies are within
the range of pivotal clinical trial estimates. Several
studies reported 4-year survival rates in patients with
early BC (EBC) at ∼90%41 50 and in patients with MBC
at 41%.43 The 4-year relapse-free survival rate in MBC
was 76%.50 An Italian study found no difference in OS
(HR 0.79 (95% CI 0.50 to 1.26)) between metastatic
patients previously treated with trastuzumab for EBC
who are subsequently treated with trastuzumab for MBC
and patients ﬁrst diagnosed with MBC receiving trastuzu-
mab for MBC.42 An Australian study of patients with
HER2-positive MBC estimated a median OS of
29.9 months.38
Issues, such as factors associated with use of trastuzu-
mab, adherence to guideline-speciﬁed treatment pat-
terns, off-label use and overall resource use, have also
been examined in a number of studies. A US study
found that tumour grade, ethnicity and area of resi-
dence were associated with use of trastuzumab for
EBC.51 The only two studies examining lapatinib use did
so in the context of quantifying resource use associated
with treatment and the factors related to adherence to
therapy. They found that costs did not differ between
trastuzumab and lapatinib therapy, but the resource use
driving costs did;54 and that prior therapy with a taxane
was associated with greater discontinuation of lapati-
nib.55 An Australian study found that 22% of patients
received trastuzumab for MBC with non-recommended
concomitant treatment partners, and ∼20% (or AUD$21
million) of trastuzumab was discarded due to regulations
around unused phial portions and weekly treatment
schedules.35
Our research programme aims to provide insights into
issues that clinical trials are not designed to address and
contribute additional knowledge to the current evidence
base on the real-world use of HER2 therapies. Speciﬁcally,
we will examine real-world patterns of prescribing, side-
effect monitoring and outcomes (see table 1, column 3)
using one of the largest whole-of-population cohorts of
HER2-positive patients and one of the longest follow-up
periods, internationally. We will:
1. Compare the real-world use and outcomes with clin-
ical trials and guideline recommendations.
2. Determine the duration of HER2-targeted therapies
and the long-term beneﬁts and toxicities of
treatment.
3. Determine the outcomes of patients receiving
HER2-targeted therapies for MBC who also received
HER2-targeted therapies for EBC.
4. Estimate total resources—medicines and health ser-
vices—used by patients treated with HER2-targeted
therapies, and factors associated with resource usage.
5. Explore the patient and treatment characteristics
associated with survival.
6. Assess the impacts of policy interventions on treat-
ment patterns and outcomes.
METHODS
Study setting
Australia maintains a publicly funded universal health-
care system entitling all citizens and permanent resi-
dents to a range of subsidised health services. This
includes free treatment in public hospitals (funded
jointly by the Commonwealth and State/Territory gov-
ernments) and subsidised treatment in private hospitals
(funded jointly by the Commonwealth and private
health insurance). Outpatient services, including consul-
tations with medical and selected healthcare profes-
sionals, are funded by the Commonwealth’s Medicare
Beneﬁts Schedule (MBS). Medicines prescribed in the
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community and some hospitals are funded by the
Commonwealth’s Pharmaceutical Beneﬁts Scheme
(PBS). The Australian Department of Human Services
(DHS) maintains records of medicines dispensed (PBS)
and medical services provided (MBS) to patients for the
purpose of reimbursement.
Medicines of interest, funding and access restrictions
There are currently four publicly subsidised
HER2-targeted therapies available in Australia. Medicines
subsidised on the PBS are approved by the Pharmaceutical
Beneﬁts Advisory Committee (PBAC) on the basis of efﬁ-
cacy and cost-effectiveness.56 57 Trastuzumab (Herceptin,
Table 1 Characteristics of published studies that use population-based administrative data and comparison with current
programme
Published studies*
Current
programme
EBC Reference # MBC Reference # EBC MBC
Country
Australia 0 – 4 35–38 X X
Canada 1 39 0 –
Italy 3 40–42 2 42 43
USA 10 44–53 4 45 46 54 55
Observation start year
1998–2000 4 45 46 48 49 3 45 46 55
2001–2005 5 39 44 47 50 52 4 35–38 X
2006–2010 5 40–42 51 53 3 42 43 54 X
Number of observation years
<5 4 40–42 51 2 42 43
5–10 10 39 44–50 52 53 7 35–38 45 46 54 X
>10 0 – 1 55 X
Medicine focus
Trastuzumab 14 39–42 44–53 10 35–38 42 43 45 46 54 55 X
Lapatinib 0 – 1 55
Trastuzumab and lapatinib 0 – 1 54 X
HER2-positive sample size
<1000 patients 6 42 45 48 49 51 53 5 42 43 45 54 55
1000–2000 patients 0 – 1 35
2000–3000 patients 6 40 41 44 46 47 52 1 46
3000–4000 patients 2 39 50 3 36–38
5000–12 000 patients – – – – X X
Age
Patients >65 only 6 44–47 49 51 2 45 46
Patients of all ages 9 39–42 48 50 52 53 8 35–38 42 43 54 55 X X
Sex
Women 12 39–42 45–52 10 35–38 42 43 45 46 54 55 X
Women and men 2 44 53 0 – X
Study focus
Treatment patterns
Duration of therapy 4 40 41 47 53 5 35 37 38 54 55 X X
Schedules/dosing 2 44 47 2 35 38 X X
Concomitant cancer therapies 13 39–41 44–53 8 35 37 38 43 45 46 54 55 X X
Cancer therapies prior to/following HER2 therapy 2 42 52 3 42 54 55 X X
Non-cancer treatments 2 40 41 0 – X X
Guideline-recommended care 2 45 47 3 35 37 45 X X
Monitoring
Cardiac 0 – 3 35–37 X
Other medical services 0 – 2 54 55 X
Outcomes
PFS/DFS, associated factors 3 41 50 52 1 38
OS, associated factors 5 41 42 45 50 52 4 38 42 43 45 X X
Cardiovascular events, associated factors 7 39 40 44 46–49 2 43 46
*Shih et al, Tsai et al and Negri et al include patients with EBC and MBC, and each study is included in both columns.
DFS, disease-free survival; EBC, early breast cancer; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS,
overall survival; PFS, progression-free survival.
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Genentech, South San Francisco, California, USA;
Hoffmann-La Roche, Basel, Switzerland) for metastatic
disease was not considered to be cost-effective by PBAC,
but was subsidised through a separate programme.58 From
December 2001 until June 2015, the Herceptin Programme
provided free access to trastuzumab for MBC. The
Herceptin Programme was also administered by the DHS
until its close in June 2015; since July 2015, trastuzumab
for MBC has been PBS-subsidised.59–63 Trastuzumab for
adjuvant and neoadjuvant treatment was listed on the PBS
in October 2006 and December 2012, respectively.
Lapatinib (Tykerb, GlaxoSmithKline, Research Triangle
Park, North Carolina, USA) was listed on the PBS as a
second-line treatment for HER2-positive MBC in May 2008.
Pertuzumab (Perjeta, Genentech, South San Francisco,
California, USA; Hoffmann-La Roche, Basel, Switzerland)
and trastuzumab emtansine (T-DM1) (Kadcyla, Genentech,
South San Francisco, California, USA; Hoffmann-La
Roche, Basel, Switzerland) were listed for ﬁrst-line and
second-line MBC therapy, respectively, in July 2015.
To ensure that HER2-targeted agents are administered
according to clinical trial evidence, the PBS places restric-
tions on their use. These restrictions have changed with
emerging evidence and are summarised in table 2.
Data sources
Our current holdings include unit-record data on
patient demographics, PBS dispensing records (all
PBS-funded medicines, not just cancer medicines)
and all MBS medical services records for persons
treated with trastuzumab and lapatinib between
January 2001 and April 2014. We will receive annual
data updates. T-DM1 and pertuzumab were funded in
Australia in July 2015, and patients treated with these
medicines will form part of our subsequent data
updates (table 3).
Australian law prevents the DHS from linking PBS to
MBS records without the explicit consent of patients.66
As a result, our data holding for patients receiving
PBS-funded trastuzumab (in the adjuvant or neoadju-
vant settings) is currently limited to patient information
and PBS dispensing history only. However, due to the
Herceptin Programme arrangements (active until 2015),
DHS can link PBS records and MBS records to Herceptin
Programme records, separately, and supply the data, so
that we can undertake the ﬁnal merging of the entire
data holdings. Therefore, our holdings for patients
accessing trastuzumab for metastatic disease consist of
patient information, PBS history (where we ascertain all
other cancer therapies and other prescribed medicines),
MBS history and Herceptin Programme data. We have
similar data for patients who received lapatinib because
access to lapatinib under the PBS required that patients
progressed while receiving trastuzumab for metastatic
disease, which had been only been possible through the
Herceptin Programme.
Data access
Data extraction was performed by the DHS who assigned
a unique scrambled ID and extracted all patient infor-
mation and all dispensing records (not just
HER2-targeted medicines) associated with that ID. For
Herceptin Programme participants, the DHS also extracted
medical services records from MBS data. Those records,
with the unique ID and requested variables, were then
sent to the researchers stripped of identifying informa-
tion such as name and address. The researchers joined
the data sets using the unique ID.
Study design
This ongoing research programme will comprise a series
of retrospective cohort studies of all Australian patients
with HER2-positive BC accessing publically subsidised
treatment with HER2-targeted agents from 2001 to 2020.
Study population
As this is an ongoing study, the characteristics of the
population will change over time. Characteristics of the
study population at the date of ﬁrst dispensing of
HER2-targeted therapy, stratiﬁed by treatment setting,
are summarised below (table 4).
In our current data holdings, there are 5631 patients
who received trastuzumab and 1099 patients who received
lapatinib for MBC; 11 406 patients received trastuzumab in
the early-stage and neoadjuvant settings. Overall, there are
1.1 million dispensing records associated with Herceptin
Programme participants and 1.7 million records associated
with patients with EBC and neoadjuvant patients (table 5).
Herceptin Programme participants generated 2.2 million
medical services claims. In total, there are 25 437 total
person years in the Herceptin Programme dispensing records;
59 154 person years in EBC/neoadjuvant dispensing
records and 27 763 person years in the Herceptin Programme
medical services claims (table 5).
Three thousand one hundred and thirteen of the
MBC patients (55%) and 6439 of the EBC patients
(56%) received at least one dispensing of a hormonal
therapy. There were 125 257 taxane dispensings and
35 664 anthracycline dispensings. With a median obser-
vation time of 49.8 months (IQR 39.5–94.8) from ﬁrst
medicine dispensing or medical service until death or
censor date (31 March 2014), 3777 of the patients
treated for MBC (67%) have died and 898 of the
patients treated for EBC (8%) have died. Reﬂecting the
population distribution of Australia, more than half of
patients in all treatment settings resided in New South
Wales and Victoria and more than two-thirds of all
patients lived in major cities (not shown in table 4).
Among patients with MBC, at least 81% received at least
one dispensing of a pain medication; 48% received
medication for the treatment of hypertension or angina;
40% received an antidepressant and 23% received an
antianxiety medication. Among patients with EBC, 64%
received at least one dispensing of a pain medication;
40% received medication for hypertension or angina;
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Table 2 Access restrictions to HER2-targeted therapies in Australia
(a) Subsidy restrictions: trastuzumab for HER2+ metastatic breast cancer
2001–2005 2006–2015 2015—present*
Treatment qualification: patients must have HER2 overexpression by
▸ IHC 3+ or ISH ISH No change
Trastuzumab treatment
▸ In combination with taxanes in patients not previously receiving
chemotherapy for MBC
▸ As monotherapy in patients previously receiving chemotherapy
for MBC
▸ Weekly dosing regimen
As per 2001–2005 plus
▸ weekly or 3-weekly
dosing regimen
As per 2001–2015 plus
▸ in combination with any
chemotherapy except
nab-paclitaxel
Cardiac monitoring
▸ None required None required ▸ ECHO or MUGA at
baseline then at
3-monthly intervals
(b) Subsidy restrictions: trastuzumab for HER2+ early breast cancer
2006–2015 2015—present
Treatment qualification: patients must have…
▸ HER2 overexpression demonstrated by ISH
▸ Undergone surgery for breast cancer
No change
Trastuzumab treatment
▸ Started in combination with chemotherapy
▸ Patients are eligible for 52 weeks of treatment
No change
Cardiac monitoring
▸ ECHO or MUGA at baseline then at 3-monthly intervals
▸ Left ventricular ejection fraction (LVEF) > 45%
▸ No symptomatic heart failure
No change
(c) Subsidy restrictions: lapatinib for HER2+ metastatic breast cancer
2008–2010 2010–2015 2015—present
Treatment qualification: patients must have…
▸ HER2 overexpression demonstrated by ISH
▸ Prior taxane for ≥3 cycles; or intolerance to taxane
▸ Disease progression while receiving trastuzumab for MBC
No change No change
Lapatinib treatment
▸ As sole PBS-subsidised anti-HER2 treatment
▸ In combination with capecitabine
▸ Patients CANNOT receive trastuzumab subsequent to receiving
lapatinib
▸ As sole
PBS-subsidised
anti-HER2 treatment
▸ In combination with
capecitabine
▸ Patients CAN receive
trastuzumab
subsequent to
receiving lapatinib
No change
Cardiac monitoring
▸ ECHO or MUGA at baseline then at discretion of clinician No change ▸ ECHO or MUGA at
baseline then at
3-monthly intervals
(d) Subsidy restrictions: trastuzumab for HER2+ neoadjuvant therapy
2012—present
Treatment qualification: patients must have…
▸ HER2 overexpression demonstrated by ISH
▸ Not undergone surgery for breast cancer
Trastuzumab treatment
▸ In combination with chemotherapy
▸ Patients are eligible for 52 weeks of treatment
Continued
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35% received an antidepressant and 17% received an
antianxiety medication.
Patients with MBC accessing trastuzumab had a
median of 54 medical service claims per person, per
year (IQR 23–106). The majority of claims relate to path-
ology services (40.4%) and consultations and visits with
healthcare professionals (27%). Patients who also
received lapatinib for MBC had 536 370 medical service
claims, with a median of 68 (27–121) per person, per
year. These services followed a similar pattern to those
for all trastuzumab patients.
Outcomes of interest and statistical analyses
We will use a range of pharmacoepidemiological and
statistical analyses to address our aims.
Patterns of use
We will summarise the prescribing patterns of
HER2-targeted therapies, including agent used, line of
therapy, partnering therapy (chemotherapy, other
HER2-targeted therapy and endocrine therapy) and dur-
ation of therapy.
We will report the characteristics of patients dispensed
HER2-targeted therapies, including age, sex, geograph-
ical remoteness, socioeconomic status, HR status and
presence of comorbidities at dispensing of
HER2-targeted therapy and over time. Age, sex, geo-
graphical remoteness and socioeconomic status will be
ascertained from the patient information data sets. We
will deﬁne HR status using a validated proxy and deﬁne
the number and nature of comorbidity from dispensing
claims using the validated RxRisk index.67–69
Comparison of real-world use with clinical trials and
prescribing guidelines
We will compare the duration of therapy (based on dis-
pensing records) and survival outcomes associated with
HER2-targeted therapies to those from published clin-
ical trials; we will not undertake comparative efﬁcacy
analyses as it is prone to confounding by indication bias.
We will estimate OS through Kaplan-Meier methods. We
will use descriptive statistics to compare characteristics of
patients treated with these medicines in the real-world
setting to those treated in clinical trials. Finally, we will
Table 2 Continued
(d) Subsidy restrictions: trastuzumab for HER2+ neoadjuvant therapy
2012—present
Cardiac monitoring
▸ ECHO or MUGA at baseline then at 3-monthly intervals
▸ LVEF >45%
▸ No symptomatic heart failure
(e) Subsidy restrictions: pertuzumab for HER2+ metastatic breast cancer
2015—present
Treatment qualification: patients must have…
▸ HER2 overexpression demonstrated by ISH
▸ WHO performance status of 0 or 1
▸ No prior HER2 therapy for MBC
Pertuzumab treatment
▸ In combination with trastuzumab and a taxane (not nab-paclitaxel)
Cardiac monitoring
▸ ECHO or MUGA at baseline then at 3-monthly intervals
(f) Subsidy restrictions: Trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer
2015–2016 2016—present
Treatment qualification: patients must have
▸ HER2 over expression demonstrated by ISH
▸ WHO performance status of 0 or 1
▸ Progressed while receiving pertuzumab and trastuzumab for MBC or while receiving or
within 6 months of completing adjuvant trastuzumab
▸ Not received prior treatment with lapatinib or developed an intolerance to lapatinib
As per 2015–2016 but
▸ patients may have
received prior treatment
with lapatinib or
developed an intolerance
to lapatinibT-DM1 treatment
▸ Treatment as monotherapy No change
Cardiac monitoring
▸ ECHO or MUGA at baseline then at 3-monthly intervals No change
*Herceptin Programme ceased and trastuzumab for MBC was listed on the PBS.
ECHO, echocardiography; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridisation;
MBC, metastatic breast cancer; MUGA, multiple gated acquisition scan; PBS, Pharmaceutical Benefits Scheme.
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Table 3 Data holdings approved for the research programme
Data set
First available
date in Australia
Description Metastatic Early-stage Neoadjuvant
Trastuzumab Lapatinib T-DM1 Pertuzumab Trastuzumab Trastuzumab
2001 2008 2015 2015 2006 2012
Patient
demographics
Year of birth; sex; mm/yy of death; state of residence and
postcode of residence mapped to SLA*
X X X X X X
Patient weight Patient weight (kg) at the time of Herceptin Programme
enrolment
X X
Treatment
qualification
Patient HER2 overexpression levels and the test used to
ascertain levels (IHC or ISH).
Initial intended treatment—monotherapy or concomitant
treatment with taxanes
X X
PBS All prescribed medicines reimbursed by the PBS. Variables
include medicine name and strength, date of prescribing, date
of supply, quantity supplied/pack size, the number of repeats
allowed with the prescription, patient copayment contribution
and the cost to government
X X X X X X
Trastuzumab
supply
Dates and phial of trastuzumab dispensed to Herceptin
Programme participants
X
MBS All medical and allied health services. Variables includes the
type of service rendered—from outpatient doctor visits to
surgeries—the cost and benefit paid for the service, and the
date of service
X X
*SLA classifies geographic areas of Australia by socioeconomic profile and remoteness.64 65
IHC, immunohistochemistry; ISH, in situ hybridisation; MBS, Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Scheme; SLA, statistical local area.
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compare the real-world treatments to published treat-
ment guidelines.
Outcomes in patients who received HER2-targeted therapies
for EBC and MBC
We will identify a subset of patients who initiate trastuzu-
mab for EBC and who are subsequently trastuzumab-
treated for MBC; this patient group is underrepresented
in clinical trials. We will compare patient characteristics for
this patient group with trastuzumab-naïve MBC patients,
trastuzumab-naïve MBC patients whose ﬁrst cancer medi-
cine was trastuzumab (as a proxy for patients ﬁrst diag-
nosed with MBC) and EBC patients who do not go on to
receive trastuzumab for MBC. We will describe patterns of
treatment for each of these three patient groups and use
Cox proportional hazard regression to estimate differences
in OS between these patient groups.
Estimating total resources
We will use multiple metrics to examine the nature and
extent of resource use associated with HER2-targeted
therapy. We will report on PBS, MBS and Herceptin
Programme resource use overall and by service type and
stratify resource use by age, treatment setting, patterns
of care, socioeconomic status and remoteness. We will
examine the proportion of total resource use accounted
for by each service (eg, the proportion of total services
accounted for by medications, imaging procedures,
surgery, specialist consultations, etc). We will identify
predictors of the rate of health service usage using
Poisson regression or negative binomial regression, as
appropriate. In all models, we will consider age at initi-
ation of ﬁrst HER2-targeted therapy, geographical
remoteness, socioeconomic status, HR status and
comorbidities.
Table 4 Cohort demographic and clinical characteristics at first HER2-targeted therapy dispensing
Metastatic Early-stage
Trastuzumab Lapatinib trastuzumab
Patients with at least one dispensing (n) 5631 1099 11 406
Age, median (IQR) 56 (48–65) 56 (48–63) 54 (47–63)
Weight in kilograms at first dispensing, median (IQR) 70 (60–80) 70 (60–81) –
HER2-positive by IHC 3+, n (%) 3542 (62.9) 585 (53.2)
HER2-positive by ISH, n (%) 2193 (38.9) 496 (45.1)
Fact of death, n (%) 3777 (67.1) 892 (81.2) 898 (7.9)
Hormone receptor positive, n (%)* 3113 (55.3) 617 (56.1) 6439 (56.4)
Comorbidities†, n (%)
0–2 492 (8.7) 44 (4.0) 1928 (16.9)
3–4 921 (16.4) 149 (13.6) 3054 (26.8)
5–6 1137 (20.2) 244 (22.2) 2689 (23.6)
7+ 3081 (54.7) 662 (60.2) 3735 (32.7)
*Dispensing of a hormonal agent indicated hormone receptor positivity.
†Comorbidities assessed from dispensing claims using the RxRisk algorithm.
IHC, immunohistochemistry; ISH, in situ hybridisation; HER2, human epidermal growth factor receptor 2.
Table 5 Characteristics of data holding
Metastatic Early-stage
Trastuzumab Lapatinib Trastuzumab
Dispensing records, total (N) 1 100 594 261 496 1 763 268
Dispensing records, HER2-targeted therapy (N) 145 907 8000 171 605
Medical services records (N) 2 221 760 536 370 –
Type of medical service, overall, claims, N (%)
Pathology 897 597 (40.4) 225 210 (42.0) –
Attendances/consults/visits 599 277 (27.0) 135 521 (25.3) –
Specialist 329 077 (14.8) 79 266 (14.8) –
General practitioner 236 649 (10.7) 48 614 (9.1) –
Enhanced primary care 13 045 (0.6) 3095 (0.6) –
Practice nurse 8264 (0.4) 2100 (0.4) –
Other 12 242 (0.6) 2446 (0.5) –
Diagnostic imaging 199 411 (9.0) 48 081 (9.0) –
Radiotherapy/nuclear medicine 136 490 (6.1) 36 276 (6.8) –
Miscellaneous (eg, medical supplies) 388 985 (17.5) 91 282 (17.0) –
HER2, human epidermal growth factor receptor 2.
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Examining variations in patient response
We will examine predictors of time-to-discontinuation
and time-to-death using Kaplan-Meier curves and Cox
proportional hazards models. We will ascertain date of
death using the patient information data set. We will use
subgroup analysis to interrogate data on patients who
die during early-stage treatment or soon after its comple-
tion and those who survive for many years following initi-
ation of HER2 therapy to determine the characteristics
and patterns of treatment associated with short-term and
long-term survival.
Impact of policy interventions on treatment patterns and
outcomes
We will examine speciﬁc prescribing policies in Australia
to determine the impact they have on treatment patterns
and outcomes. For instance, during the ﬁrst 2 years of
its availability, prescribing lapatinib to a patient prohib-
ited a return to trastuzumab for that same patient. We
will explore the impact of policy changes using inter-
rupted time series methodology.36
Analyses will be performed using SAS V.9.4, Stata V.13
and R V.3.2.2.
Limitations
As in any epidemiological study, we must consider the
potential biases in our research. Some of the issues
raised in relation to administrative database research
and the conduct of pharmacoepidemiological research
in Australia are described below.
Medicine exposure
Australia maintains comprehensive pharmaceutical
claims data collections for prescribed medicines dis-
pensed in community and private hospitals, but not for
public hospital inpatients. The vast majority of oncology
protocols are administered in the outpatient setting or
to private hospital inpatients (both of which are cap-
tured in the PBS data), and we believe that the lack of
public hospital inpatient dispensing data is unlikely to
impact signiﬁcantly on the outcomes of our analyses.
In addition, the creation of PBS records is tied to
those medicines that are subsidised (in part or in full)
by the government. Subsidised medicines in Australia
require a patient copayment; AUD$38.30 at the time of
writing. Medicines whose cost is below this amount are
not subsidised by the PBS and are not recorded in the
PBS data. Therefore, the record of patients’ PBS medi-
cine use may be incomplete, limiting the scope of some
analyses.57 We do, however, have information on all PBS
medicines, including their total costs over time and the
capacity to identify patients for whom we may not have
all PBS dispensings (using their entitlement category).
We will restrict some of our analyses to persons with
complete PBS medicines ascertainment. Importantly,
the vast majority of cancer medicines are above the
copayment threshold.70 Furthermore, from July 2012
under copayment, medicines were recorded in PBS data
and these records will be a part of future data updates.
Diagnosis, outcome and covariate misclassification
Health administrative data sets lack detailed clinical infor-
mation, and we need to assess the impact of misclassifying
diagnoses and outcomes of interest. Owing to the struc-
ture of the data sets, we know that all patients with MBC
appear in Herceptin Programme data sets. For patients with
early BC, between 1 October 2006 and 30 November
2012, all dispensings of trastuzumab represent adjuvant
therapy, as this was the only PBS-funded indication
during this time. As noted earlier, the Herceptin Programme
was phased out in 2015 and trastuzumab for MBC listed
on the PBS, meaning that from late 2015 trastuzumab dis-
pensings across all treatment settings form part of the
PBS data; based on our existing current data holdings, we
will not be able to distinguish between trastuzumab sup-
plied for metastatic and early-stage disease from late
2015. Similarly, among patients with early BC from 1
December 2012, we are unable to determine which dis-
pensings represent adjuvant or neoadjuvant therapy.
To address this issue, we will obtain dispensing author-
ity codes. Authority codes are generated when the pre-
scribing doctor gains approval to administer an
authority-required medicine (such as all HER2-targeted
therapies) for a particular indication, and they will allow
us to delineate between medicines dispensed across the
different settings.
The data also lack certain important covariates, includ-
ing comorbidities, Eastern Cooperative Oncology Group
(ECOG) status and Tumour/Nodes/Metastasis (TNM)
staging. Identifying adverse events, such as cardiotoxic
events, is difﬁcult without detailed clinical information
or hospital admissions codes. Additional, external data
sets may be used to examine these issues, but we will not
attempt these analyses with our current data holdings.
We previously attempted to validate a proxy for disease
progression using dispensing claims, but demonstrated a
sensitivity of 74%, speciﬁcity of 88% and positive predict-
ive value of 61%.71 As such, we do not currently have the
capacity to accurately estimate time to progression or PFS
using dispensing claims alone. This will limit the scope of
outcomes research in the patients with early-stage disease;
at present, the main contributions based on our available
data are likely to lie in the metastatic setting.
Ethics
At the time of writing, we have ethical approval for
annual data updates until 2020.
The data for the research programme are released
without individual consent. The use and disclosure of
Commonwealth data are governed under the Privacy Act
1988. Information Privacy Principle (IPP) 2 under the
Privacy Act 1988 (Commonwealth) provides that per-
sonal information should not be used or disclosed for
any purpose other than the primary purpose of the
collection.
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We sought approval to use the data for a secondary
purpose, that of research involving data linkage.
▸ Under IPP2.1(d) use or disclosure for another
purpose is permitted if (1) it is necessary for research
and it is impracticable to gain consent and (2) the
use is in accordance with the section 95A guidelines
(which provide a process to resolve the conﬂict that
may arise between the public interest in privacy and
the public interest in medical research).
We applied for these exemptions to the current
research programme. Individual consent for the release
of data has been waived because:
▸ It is not possible or practical to obtain consent
because of the large study population (>15 000
patients), and a large proportion of patients were
likely to be deceased.
▸ Obtaining consent would prejudice the scientiﬁc
value of the research due to the high participation
rates required for unbiased samples (at least 90%)
and the Australian evidence about the sociodemo-
graphic differences between participants who consent
to data linkage research and those who do not.72 73
▸ The public interest in the research outweighs the
public interest in privacy protection, as we know little
about the way in which HER2-blockade medicines are
used in the real-world marketplace.
DISSEMINATION PLAN
We will consult clinicians, policymakers and consumers
where appropriate for guidance in interpreting and dis-
seminating our results. The outcomes of this research will
be submitted to international peer-reviewed journals; in
particular oncology, general medical and pharmacoepi-
demiology journals. We will also present our ﬁndings at
national and international oncology and pharmacoepide-
miology conferences. We will communicate study out-
comes to relevant professional cancer/oncology societies,
such as the Clinical Oncology Society of Australia and the
Medical Oncology Group of Australia, and policy groups
such as the Pharmaceutical Beneﬁts Advisory Committee
and NPSMedicinewise. We will also develop lay summar-
ies of research ﬁndings as needed.
In accordance with our DHS data agreement, we will
submit all data that will be communicated in the public
domain to the DHS for review and approval. Authorship
will be based on the International Committee of Medical
Journal Editors guidelines.74 Outcomes will also be posted
on the University of New South Wales web page of the
lead investigator and the Centre for Big Data Research in
Health website. Direct access to the data and analytical
ﬁles to other individuals or authorities is not permitted
without the express permission of the approving human
research ethics committees and data custodians.
DISCUSSION
The programme of research outlined in this protocol
will provide valuable evidence of the real-world, clinical
use and outcomes of HER2-targeted therapies. The
unique funding structure of these medicines in Australia
has created one of the largest and only whole-of-country,
HER2-targeted therapies data sets in the world.
Observational studies of the kind described in this proto-
col are particularly important, given many of the
patients treated in routine practice would not meet
typical clinical trial inclusion criteria. The existing obser-
vational research has highlighted the use of trastuzumab
in populations signiﬁcantly different from those in the
clinical trials; at present, there is limited information on
the real-world use of lapatinib and no studies addressing
T-DM1 or pertuzumab.
The strengths of this programme lie in the use of best
practice methods to examine patterns of use and long-
term outcomes associated with HER2-targeted therapy;
this is particularly important for patients with survival
times longer than the typical clinical trial follow-up period.
Given these data come from a single payer and are
national in scope, loss to follow-up is likely to be much
lower than observational studies conducted in countries
where health service provision and insurance is more frag-
mented. Owing to the whole-of-population nature of the
data, our ﬁndings are likely to be highly generalisable and
provide opportunities to extend knowledge on the popula-
tion impact of HER2-targeted therapy.
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